Cargando…

Factors precipitating erythropoiesis‐stimulating agent responsiveness in a European haemodialysis cohort: case‐crossover study

PURPOSE: Hyporesponsiveness to erythropoiesis‐stimulating agents (ESAs) is clinically and economically important in the treatment of anaemia in chronic kidney disease (CKD) patients. Previous studies focused on baseline predictors of ESA hyporesponsiveness, rather than factors associated with the tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillespie, Iain A., Macdougall, Iain C., Richards, Sharon, Jones, Vincent, Marcelli, Daniele, Froissart, Marc, Eckardt, Kai‐Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024014/ https://www.ncbi.nlm.nih.gov/pubmed/25690434 http://dx.doi.org/10.1002/pds.3755

Ejemplares similares

Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
por: Roger, Simon D, et al.
Publicado: (2017)

Development and validation of a predictive mortality risk score from a European hemodialysis cohort
por: Floege, Jürgen, et al.
Publicado: (2015)

Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13
por: Birnie, Kate, et al.
Publicado: (2017)

High cardiovascular event rates occur within the first weeks of starting hemodialysis
por: Eckardt, Kai-Uwe, et al.
Publicado: (2015)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

A prospective study of fatigue trajectories among in‐centre haemodialysis patients
por: Picariello, Federica, et al.
Publicado: (2019)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study
por: Fotheringham, James, et al.
Publicado: (2020)

Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial
por: Locatelli, Francesco, et al.
Publicado: (2012)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review
por: Devlin, Paula, et al.
Publicado: (2022)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
por: Floege, Jürgen, et al.
Publicado: (2011)

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
por: Anker, Stefan D., et al.
Publicado: (2009)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ylenia, Ingrasciotta, et al.
Publicado: (2019)

The mortality risk of overhydration in haemodialysis patients
por: Wizemann, Volker, et al.
Publicado: (2009)

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
por: Stefánsson, Bergur V., et al.
Publicado: (2011)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
por: Pirker, Robert, et al.
Publicado: (2012)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g9o5k33ei69tmkmkjl79s59n6n